Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
RTI Health Solutions
DUS1 will be conducted when the target number of new users of aclidinium monotherapy is reached, and DUS2 when the target number of new users of aclidinium fixed-dose combination with formoterol is reached.
As this was a descriptive study no primary or secondary endpoints were specified.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients in the study will be required to meet the following criteria, as ascertained from each of the automated databases:
To have at least 1 year of enrolment in the database (DUS1 and DUS2).
To have not been prescribed aclidinium bromide as monotherapy or with concomitant use of formoterol during the 6 months before the date of first prescription of aclidinium bromide (index date) in DUS1
To have not been prescribed aclidinium bromide as monotherapy, with concomitant use of formoterol, or as aclidinium/formoterol during the 6 months before the date of first prescription of aclidinium bromide (index date) in DUS2
Clareo Health | A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)
